Coronary Artery DiseaseREDEEM-CADNCT05366153
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
An observational study of Coronary Artery Disease, run by Baker Heart and Diabetes Institute at 2 sites in Australia.
Trial summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. Read more about this study
- Who is it for?
- Ages 40 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Coronary CT
- How many people
- 748 participants
- Where
- 2 sitesAustralia
- Study dates
- 18 Oct 2023to May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago
Who may be able to join
- A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Who cannot join
- Unable to provide written informed consent to participate in this study
- Known coronary artery disease at recruitment
- History of previous coronary artery disease
- Inability to acquire interpretable CT images
- Contraindications/Intolerance to or already taking statin therapy
- Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Australia2 sites, 2 recruiting
- Recruiting
Tom Marwick
Hobart, Tasmania, 7000
Kristyn Witmore, BSN, 0362268816, kris.whitmore@utas.edu.au
Tom Marwick, MBBS, 0362268816, tom.marwick@utas.edu.au
- Recruiting
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004
Cheng Soh, PhD, +61385321624, cheng.soh@baker.edu.au
Thomas Marwick, MBBS, +61385321550, tom.marwick@baker.edu.au
About this study
Official title: Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.
Read the detailed description
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.
Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
- Conditions
- Coronary Artery Disease
- Being tested
- Coronary CT
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary CTDiagnostic test
Screening/Management Plan
| Study group | Role | What they receive |
|---|---|---|
| Survivor Screening/Management Plan | In cancer survivors;
1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,
2. A clinical review to ensure optimal risk factor control and cardiac protection. Receives: Diagnostic Test: Coronary CT | |
| Non-cancer Screening/Management Plan | In matched non-cancer patients (from EDCAD trial);
1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,
2. A clinical review to ensure optimal risk factor control and cardiac protection. Receives: Diagnostic Test: Coronary CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score >0
Measured: 3 years
Secondary outcomes (3)
Proportion with critical CAD
Coronary stenosis >70% by CT coronary angiogram
Measured: 3 years
Proportion at intermediate clinical risk
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
Measured: 3 years
Statin responsiveness
Change in plaque volume
Measured: 3 year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2022
- Study start18 Oct 2023
- Primary completionMay 2026 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 748 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baker Heart and Diabetes Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Western Health, Australia, Northern Hospital, Australia, Menzies Institute for Medical Research, Peter MacCallum Cancer Centre, Australia, The Alfred
- Responsible party
- Sponsor
- Investigators
- Tom Marwick, MBBS,PhD,MPH, Principal investigator, Baker Heart and Diabetes Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05366153
- Sponsor's protocol ID
- 134-22
- Acronym
- REDEEM-CAD
- Status last verified
- Sep 2025
- First submitted
- 4 May 2022
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Soh CH, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, Marwick TH. Screening for coronary artery disease among cancer survivors: rationale and design of the REDEEM-CAD study. Cardiooncology. 2025 Feb 4;11(1):10. doi: 10.1186/s40959-025-00308-7.
PubMed 39905553
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
- ClinicalTrials.gov ID
- NCT05366153
- Acronym / sponsor ID
- REDEEM-CAD / 134-22
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 748 participants (estimated)
- Lead sponsor
- Baker Heart and Diabetes InstituteUniversity, hospital or other
- Collaborators
- Western Health, Australia, Northern Hospital, Australia, Menzies Institute for Medical Research, Peter MacCallum Cancer Centre, Australia, The Alfred
- Study start
- 18 Oct 2023 (actual)
- Primary completion
- May 2026 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 9 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.
Detailed description
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.
Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Survivor Screening/Management Plan | – | Diagnostic Test: Coronary CTIn cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection. |
| Non-cancer Screening/Management Plan | – | Diagnostic Test: Coronary CTIn matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection. |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago
Key inclusion criteria (1 listed)
- A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Key exclusion criteria (6 listed)
- Unable to provide written informed consent to participate in this study
- Known coronary artery disease at recruitment
- History of previous coronary artery disease
- Inability to acquire interpretable CT images
- Contraindications/Intolerance to or already taking statin therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary CTScreening/Management Plan | Diagnostic test | Non-cancer Screening/Management Plan, Survivor Screening/Management Plan |
Primary outcome
Proportion of evaluated patients who should undergo CAD prevention
Time frame: 3 years
High clinical risk, or intermediate risk with CAC score >0
3 secondary outcomes
Proportion with critical CAD
Time frame: 3 years
Proportion at intermediate clinical risk
Time frame: 3 years
Statin responsiveness
Time frame: 3 year follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Derived from this study: PubMed 39905553Soh CH, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, Marwick TH. Screening for coronary artery disease among cancer survivors: rationale and design of the REDEEM-CAD study. Cardiooncology. 2025 Feb 4;11(1):10. doi: 10.1186/s40959-025-00308-7.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tom Marwick, MBBS,PhD,MPH principal investigator
Baker Heart and Diabetes Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Baker Heart and Diabetes Institute at 2 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tom Marwick, MBBS,PhD,MPH (+61 3 8532 1550, tom.marwick@baker.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of evaluated patients who should undergo CAD prevention (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05366153, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.